DEF: Co-Diagnostics Seeks Shareholder Approval for 2025 Equity Incentive Plan and Director Elections

Co-Diagnostics is holding its annual shareholder meeting on May 28, 2025, to vote on director elections, adoption of a new equity incentive plan, executive compensation, and ratification of the company's accounting firm.

Summary

• Co-Diagnostics, Inc. will hold its Annual Meeting of Shareholders on May 28, 2025, at its Salt Lake City offices.
• Shareholders of record as of April 7, 2025, are entitled to vote.
• The meeting will address the election of five directors, approval of the 2025 Equity Incentive Plan, an advisory vote on executive compensation, and ratification of Tanner LLC as the independent accounting firm for the fiscal year ending December 31, 2025.
• The Board of Directors recommends voting for all proposals.
• The company is using the SEC's Notice and Access model for proxy materials, primarily delivering them via the Internet.
• The proposed 2025 Equity Incentive Plan seeks authorization for the issuance of up to 6,700,000 shares of common stock.
• The plan aims to attract and retain key employees, non-employee directors, and consultants.
• The plan includes provisions such as no liberal change-in-control definition, no liberal share recycling, and no repricing of stock options without shareholder approval.
• The company's executive compensation programs are designed to reward named executive officers (NEOs) for achieving financial and strategic goals.
• The advisory vote on executive compensation (say-on-pay) allows shareholders to express their opinion on the compensation of the NEOs.
• The Audit Committee has appointed Tanner LLC as the independent registered public accounting firm for the fiscal year ending December 31, 2025, subject to shareholder ratification.
• The aggregate fees and expenses for professional services rendered by Tanner LLC for the years ended December 31, 2024 and 2023, were $194,923 and $442,649, respectively.

Sentiment

Score: 7

Explanation: The document is primarily informational and procedural, outlining the agenda for the annual shareholder meeting and seeking approval for routine corporate governance matters. The tone is professional and straightforward, with a positive outlook on the company's future.

Positives

• The proposed 2025 Equity Incentive Plan is designed to attract, retain, and motivate key personnel.
• The plan includes shareholder-friendly provisions such as prohibiting repricing of stock options without shareholder approval.
• The company is committed to aligning executive compensation with shareholder interests.
• The Board of Directors is composed of a majority of independent directors.
• The company has adopted a code of ethics for its principal executive officer and senior finance officers.
• The company has an insider trading policy to promote compliance with insider trading laws.

Negatives

• The company is a smaller reporting company and takes advantage of reduced disclosure requirements.
• The company's cumulative TSR and Net Income decreased from 2023 to 2024.

Risks

• The success of the Equity Incentive Plan depends on the Committee's ability to effectively administer it and select appropriate recipients.
• The advisory vote on executive compensation could result in negative feedback from shareholders.
• Failure to ratify the appointment of Tanner LLC could require the Audit Committee to reconsider its choice of accounting firm.
• The company's future performance is subject to various risks inherent in its business and industry.

Future Outlook

The company aims to continue its success by providing incentives to attract and retain key employees, non-employee directors, and consultants and align their interests with those of our shareholders.

Management Comments

• OUR BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS THAT YOU VOTE FOR EACH OF THE PROPOSALS.
• The proxy statement accompanying this notice provides a more complete description of the business to be conducted at the Annual Meeting.
• We encourage you to read the proxy statement carefully and in its entirety.

Industry Context

This announcement is typical for publicly traded companies as they prepare for their annual shareholder meetings, addressing corporate governance matters, executive compensation, and the selection of auditors.

Comparison to Industry Standards

• The structure of the board and its committees aligns with standard corporate governance practices for publicly listed companies.
• The use of equity incentive plans is a common method for aligning the interests of management and shareholders, similar to practices at companies like Exact Sciences, Hologic, and QuidelOrtho.
• The disclosure of executive compensation follows SEC guidelines, providing transparency to shareholders, which is consistent with industry norms.
• The process for selecting and ratifying an independent accounting firm is a standard practice to ensure audit independence and integrity, similar to practices at companies like Abbott Laboratories and Danaher Corporation.

Related Party Transactions

• Seth Egan, the Company's Chief Commercialization Officer, and Winston Egan, the Company's Director of Customer Experience, are each sons of Dwight Egan, the Company's President and Chief Executive Officer and Chairman of the Board.
• During the year ended December 31, 2024, total compensation paid to Seth Egan, including salaries, bonuses, and the grant date fair value of equity awards which vest over three years, was $0.4 million, and total compensation paid to Winston Egan, including consulting fees, salaries, and bonuses, was $0.1 million.
• Prior to the acquisition of Advanced Conceptions by the Company in December 2021, the Company's President, Richard Abbott was serving as President of Advanced Conception.
• At the time of the acquisition, Mr. Abbott was an indirect shareholder of Advanced Conceptions, Inc. through his fifty percent (50%) ownership interest in Whiteknob LLC.
• Whiteknob LLC owned 71.61% of Advanced Conceptions at the time of the acquisition.
• The terms of the acquisition agreement between the Company and Advanced Conceptions include the opportunity for Whiteknob LLC to earn an additional 507,386 common shares and an additional 166,503 common stock purchase warrants of Co-Diagnostics upon the achievement of certain milestones.
• Should those milestone events be achieved Mr. Abbott would have a fifty percent (50%) interest in the common shares and common stock purchase warrants.

Stakeholder Impact

• Shareholders have the opportunity to vote on key corporate governance matters.
• Employees may benefit from the proposed Equity Incentive Plan.
• The selection of an independent accounting firm ensures the integrity of the company's financial reporting.

Next Steps

• Shareholders should review the proxy materials and vote on the proposals.
• The company will hold the Annual Meeting of Shareholders on May 28, 2025.
• The company will file a Registration Statement on Form S-8 relating to the issuance of shares under the Plan with the Securities and Exchange Commission pursuant to the Securities Act of 1933, as amended, after approval of the Plan by the Company’s shareholders.

Key Dates

Keywords

Co-Diagnostics, Annual Meeting, Shareholders, Equity Incentive Plan, Executive Compensation, Directors, Tanner LLC, Proxy Statement, Corporate Governance, Voting